跳至主要内容
临床试验/2026-526096-31-00
2026-526096-31-00招募中1 期

A Randomized Study in Healthy Participants to Identify the Optimal Subcutaneous Injection Strategy for COR-1167

Corteria Pharmaceuticals2 个研究点 分布在 1 个国家目标入组 20 人开始时间: 2026年5月5日最近更新:
适应症

试验速览

阶段
1 期
状态
招募中
入组人数
20
试验地点
2

研究概览

简要总结

暂无简介。

入排标准

年龄范围
18 years 至 65+ years(18-64 Years, 65+ Years)
接受健康志愿者
是

入选标准

  • 未提供

排除标准

  • 未提供

研究者

申办方类型
Pharmaceutical company
责任方
Principal Investigator
主要研究者

Chief Medical Officer - Francesca Lawson

Scientific

Corteria Pharmaceuticals

研究点 (2)

Loading locations...

相似试验

尚未招募
1 期
A study in healthy people or otherwise healthy with overweight or obesity to compare 2 formulations of survodutide given in different ways, either as a pre-filled syringe or a pen-like injectorHealthy volunteer trial
2024-519614-30-00Boehringer Ingelheim International GmbH56
招募中
1 期
A study in healthy people or otherwise healthy but overweight or obese to compare 2 formulations of survodutide given in different ways, either as a pre-filled syringe or a pen-like injectorHealthy volunteer trial
2025-524135-39-00Boehringer Ingelheim International GmbH56
招募中
1 期
Study in healthy male participants to compare the blood levels after epoetin alfa (Blau EPO) and Erypo, administered as multiple intravenous injections as well as safety, tolerability and the effects on certain blood values.Treatment of symptomatic anemia associated with chronic renal failure:
2025-522246-43-00Blau Farmaceutica S.A.124
已完成
1 期
A two-part trial in healthy volunteers to find out how long JNJ-77242113 stays in and acts on the body when administered as different tablet formulations and under different food and water conditions, and to assess the acceptability profile (taste, palatability, and smell) of JNJ-77242113 formulations.Inflammatory Conditions
2024-512220-11-00Janssen Cilag International76
招募中
1 期
A study in healthy people to test how 3 different formulations of BI 764198 are taken up in the body and how this is influenced by foodhealthy volunteer trial
2024-519615-34-00Boehringer Ingelheim International GmbH17